Allergy Immunotherapy Market 2018; Competitive Players is Enhancing the Growth of the Market at The CAGR of 10.85% by 2023

Allergy Immunotherapy Market Scenario:

The market for allergy immunotherapy is growing at a swift pace. The market is expected to grow at the CAGR of ~10.85% during the forecast period and is estimated to reach USD 4,324.7 million by 2023. According to a recent study published by the Market Research Future analysts, the global allergy immunotherapy market is growing at a double digit growth rate; mainly due to launch of the new sublingual immunotherapies in emerging economies, introduction of several allergen immunotherapy tablets (AITs) by major players, increase in risk factors causing allergies, rise in the screening rate for allergies, and current reimbursement scenario.

Get Exclusive Sample Copy of Allergy Immunotherapy Market spread across 88 Premium Pages, 10+ and Supported with Full TOC, is Available @ https://www.marketresearchfuture.com/sample_request/1517

Top Players:

Some of the key players in this market are: ALK Abello A/S (Denmark), Allergy Therapeutics (UK), Circassia (UK), DBV Technologies (France), Stallergenes Greer (UK), Merck KGaA (Allergopharma) (Germany), HAL Allergy Group (Netherlands), and others.

By Geography:

Europe is holding the largest market share in global immunotherapy market. The biggest factor in this large share is the huge patient population for the different types of allergies. Some major factors that attribute the growth of Europe immunotherapy market are, rise in prevalence of chronic diseases like allergy, asthma, diabetes and hypertension.

Americas is the second largest region in the allergy immunotherapy market. The growth in the American market is majorly due to the rise in the patient population and the number of product launches in recent years. To increase their share in the market companies are introducing more and more allergen immunotherapy tablets (AITs) in potential markets. For instance, products such as Mitizax (HDM) tablets, Merck’s Grastek (grass), Ragwitek (ragweed), and Greer’s Oralair (grass) were launched in the U.S. in between 2014-2015.

Asia Pacific region is far behind the major two regions in terms of value. Some of the reasons include non-existence of Japanese market for allergy immunotherapy, despite having a large population with allergic rhinitis, fewer than 6,000 patients were treated with Specific Immunotherapy in 2013.

Avail Stunning Discount @ https://www.marketresearchfuture.com/check-discount/1517

Segmentation:

Global Allergy Immunotherapy market has been segmented on the basis of allergy type which comprise of allergic rhinitis, allergic asthma, peanut allergy, cat allergy, and other allergies.

On the basis of treatment, it is segmented into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy, and Specific Immunotherapy (SIT). Sublingual Immunotherapy is further sub-segmented into sublingual immunotherapy drops, and sublingual immunotherapy tablets.

Major TOC of Global Allergy Immunotherapy Market Research Report Forecast to 2023:

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY$

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGY TYPE

7 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TREATMENT

8 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY REGION

9 COMPANY SHARE ANALYSIS

10 COMPANY PROFILE

Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/1517

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.